PDGF-induced PI3K-mediated signaling enhances the TGF‑β‑induced osteogenic differentiation of human mesenchymal stem cells in a TGF-β-activated MEK-dependent manner
- Authors:
- Published online on: December 27, 2013 https://doi.org/10.3892/ijmm.2013.1606
- Pages: 534-542
-
Copyright: © Yokota et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
Abstract
Introduction
Bone formation and remodeling occur throughout development and adult life. The formation of new bone is a complex cascade, involving cell proliferation, osteogenic cell differentiation, extracellular matrix (ECM) maturation and matrix mineralization. Bone remodeling depends on osteoblasts (OBs), osteocytes and osteoclasts (1). Mesenchymal stem cells (MSCs) differentiate into OBs and synthesize and secrete bone matrix, which subsequently becomes mineralized tissue. Once embedded into the bone matrix, OBs further differentiate into osteocytes.
MSCs were first derived from bone marrow and are characterized by their self-renewal ability and their capacity to develop into a variety of mesenchymal tissues (2–4). The expansion of human bone marrow-derived MSCs (BM-MSCs) in vitro and their subsequent autoimplantation may be used for stem cell therapy without the risk of rejection by the immune system. BM-MSCs differentiate into OBs, chondrocytes and adipocytes (5) and are therefore considered the main source of bone regeneration and remodeling during homeostasis (6–9). Much of this process depends on the ability of MSCs to proliferate and differentiate under the influence of biologically active molecules (i.e., growth factors) (10–13). The role of growth factors in bone repair is widely recognized, particularly for platelet-derived growth factor (PDGF), insulin-like growth factor-I (IGF-I), vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β), all of which are inducers, particularly in osteoprogenitor cells (14). These growth factors are usually stored in the ECM; however, following injury, they are actively released by the ECM, cells and platelets.
TGF-β is one of the most abundant growth factors in the bone matrix (15) and regulates osteoblastic differentiation in a variety of ways, such as by stimulating the proliferation and development of early OBs, although it inhibits their maturation and mineralization (16). TGF-β is released from the bone surface and recruits MSCs to bone-resorptive sites, where they undergo differentiation into mature OBs, thus coupling bone resorption with bone formation (17). TGF-β activates intracellular effectors, such as mitogen-activated protein kinases (MAPKs) and Sma- and Mad-related proteins (Smads) (18–20). There are at least three distinctly regulated groups of MAPKs: extracellular signal-related kinases (ERKs), Jun N-terminal kinases (JNKs) and p38 MAPKs (p38). The activation of the ERK pathway mediates the differentiation of BM-MSCs and that of the pre-adipocyte cell line, 3T3 L1, into mature adipocytes. It also regulates the proliferation and differentiation of bone cells and BM-MSCs during osteogenic differentiation (21). JNK and p38 are activated in human and mouse OBs to regulate bone resorption (22,23).
PDGF is a polypeptide growth factor secreted from cytokine-laden granules of aggregated platelets early after tissue injury (24,25). PDGF is mainly produced by platelets and has been implicated in the repair of tissue damage, such as fractures (26). PDGF consists of A, B, C and D isoforms, and forms homo or hetero dimers, such as PDGF-AA or PDGF-AB (26). PDGF-BB exhibits the strongest activity of these isoforms (26) and has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with bone defects in oral and maxillofacial regions (27–30). However, the specific molecular mechanisms by which PDGF regulates the activity of multiple cell types to control tissue development are not yet fully understood. Much of the research in this area has focused on the role of PDGF in controlling the vascularization of nascent tissue, forming within the wound site (31). PDGF indirectly regulates bone regeneration by increasing the expression of angiogenic molecules, such as VEGF (32), hepatocyte growth factor (33) and that of the proinflammatory cytokine, interleukin-6 (34); VEGF is a particularly important molecule in bone regeneration (35). In general, PDGF binding leads to autophosphorylation on multiple tyrosine residues, thereby activating several downstream cascades, such as ERK belonging to MAPKs, phosphoinositide-3-kinase (PI3K)/Akt, Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways (36,37). Osteogenic progenitor cells respond to PDGF ligand-binding by the activation of Src tyrosine kinases (38–40) and of the Akt protein kinase and Grb2-mediated ERK-signaling (40). Consequently, PDGF increases the pool of osteogenic cells at the injury site, acting as a chemotactic agent and mitogen (41).
Even though the effects of TGF-β or PDGF alone on the osteogenic differentiation of undifferentiated mesenchymal cells have been reported in detail (17,40,42), their combined effects still remain unknown to date. In this study, we investigated the osteogenic differentiation of human MSCs (hMSCs) following stimulation with exogenous TGF-β and PDGF. We also investigated the mechanisms through which intracellular signals induced by TGF-β and/or PDGF control the osteogenic differentiation of hMSCs.
Materials and methods
Reagents
Recombinant human TGF-β and PDGF, as well as the MAPK/ERK kinase (MEK) inhibitor, U0126, and the PI3K inhibitor, LY294002, were purchased from Calbiochem (La Jolla, CA, USA).
Cell culture and osteogenic differentiation
The human BM-MSC line, UE7T-13, the lifespan of which was prolonged by infection with a retrovirus encoding human papillomavirus E7 and human telomerase reverse transcriptase (hTERT) (43,44), was purchased from the Health Science Research Resources Bank (JCRB no. 1154, Japan Health Sciences Foundation, Tokyo, Japan). The UE7T-13 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; PAA Laboratories, Piscataway, NJ, USA) at 37°C in a humidified incubator with an atmosphere of 5% CO2. To induce osteogenic differentiation, the UE7T-13 cells were cultured in 24-well culture plates (Nunc, Roskilde, Denmark) containing basal osteogenic differentiation medium (BODM) [α-MEM (Sigma) supplemented with 100 nM dexamethasone (Sigma), 50 μg/ml ascorbic acid (Nacalai Tesque, Kyoto, Japan), 10 mM β-glycerophosphate (Sigma) and 10% FBS (PAA Laboratories)] containing TGF-β and/or PDGF. Half of the medium in each dish was changed every 2–3 days.
Alkaline phosphatase (ALP) staining
The UE7T-13 cells were cultured in 24-well plastic culture plates or Osteologic™ discs (BD Biosciences, Franklin Lakes, NJ, USA) (a proprietary hydroxyapatite substitute for bone mineral) containing BODM supplemented with TGF-β and/or PDGF for 1 week. The surface of the Osteologic cell culture disc is coated with calcium phosphate. The cells were then stained with ALP using the TRAP/ALP staining kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan) according to the manufacturer’s instructions.
Alizarin red staining
Confluent UE7T-13 cells were cultured in 24-well plastic culture plates containing BODM supplemented with TGF-β and/or PDGF. After 2 weeks, bone matrix mineralization was evaluated by Alizarin red S (Sigma) staining. Alizarin red was extracted by the addition of 10% cetylpyridinium chloride (Sigma) in 8 mM Na2HPO4 (Wako Pure Chemical) and 1.5 mM KH2PO4 (Wako Pure Chemical Industries, Ltd.) while the absorbance was measured on an MPR-A4i microplate reader (Tosoh Co., Tokyo, Japan) at 540 nm.
RNA isolation and quantitative RT-PCR (qRT-PCR)
Confluent UE7T-13 cells in 24-well plastic culture plates or Osteologic discs were cultured in BODM containing TGF-β and/or PDGF. After 1 week of culture, total RNA was isolated using Isogen reagent (Nippon Gene Co., Ltd., Tokyo, Japan) according to the manufacturer’s instructions. cDNA was synthesized from total RNA with the PrimeScript RT reagent kit (Takara Bio, Inc., Shiga, Japan). qRT-PCR was performed on a Thermal Cycler Dice Real Time System (Takara Bio, Inc.) with SYBR Premix Ex Taq II (Takara Bio, Inc.) and specific oligonucleotide primers (presented in Table I). The mRNA expression levels of runt-related transcription factor 2 (RUNX2), ALP, liver/bone/kidney (ALPL), collagen, type I, alpha 1 (COL1A), secreted phosphoprotein 1 (osteopontin, SPP1), integrin-binding sialoprotein (bone sialoprotein, IBSP), and bone gamma-carboxyglutamate (gla) protein (osteocalcin, BGLAP) were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and the relative expression levels were expressed as the fold change relative to the corresponding control.
Western blot analysis
The UE7T-13 cells were washed twice with PBS and then lysed in RIPA buffer (50 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) containing protease and phosphatase inhibitor cocktails (Sigma). The protein content was measured with BCA reagent (Pierce Biotechnology, Inc., Rockford, IL, USA). Equivalent protein samples were separated by 10–20% SDS-polyacrylamide gradient gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA, USA). After blocking with 5% non-fat dry milk in TTBS (50 mM Tris-HCl, pH 7.2, 150 mM NaCl, and 0.1% Tween-20), the membrane was incubated with a primary anti-Akt (Cell Signaling Technology, Inc., Danvers, MA, USA), anti-phospho-Akt (Ser473) (p-Akt, Cell Signaling Technology, Inc.), anti-p44/42 MAPK (ERK1/2, Cell Signaling Technology, Inc.), anti-phospho-p44/42 MAPK (Thr202/Tyr204) (p-ERK, Cell Signaling Technology, Inc.) antibodies, and anti-β-actin (clone C4, Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibody as the loading control for normalization. The blots were then incubated with ALP-conjugated secondary antibody and developed using the BCIP/NBT membrane phosphatase substrate system (KPL). Densitometry was performed using ImageJ software (version 1.44). Data are expressed as the ratio of phosphorylated to total molecular bands.
Statistical analysis
Data are presented as the means ± standard deviation (SD). Statistical analysis was performed by using the Student’s t-test, and values of p<0.05 were considered to indicate statistically significant differences.
Results
PDGF markedly enhances the TGF-β-induced ECM mineralization in hMSCs
In general, mesenchymal cells that differentiate into OBs induce the mineralization of the the ECM (45–47). We investigated the TGF-β-mediated induction of the osteogenic differentiation of the BM-MSC cell line, UE7T-13, by using Alizarin red staining to assess ECM mineralization. As illustrated in Fig. 1A, TGF-β induced matrix mineralization in the UE7T-13 cells in a dose-dependent manner (1.0–5.0 ng/ml). We then examined the synergistic effects of PDGF and TGF-β on osteogenic differentiation. Alizarin red staining of TGF-β- and PDGF-stimulated cells revealed that the TGF-β (5 ng/ml)-induced matrix mineralization was enhanced by PDGF (10 ng/ml), whereas PDGF alone did not induce mineralization (Fig. 1B).
TGF-β and PDGF synergistically upregulate the transcript levels of ALPL and IBSP in hMSCs
To elucidate the molecular mechanisms underlying the synergistic effects of TGF-β and PDGF on osteogenic differentiation, we investigated the transcript expression of osteogenic differentiation markers in UE7T-13 cells by qRT-PCR. As shown in Fig. 2B, TGF-β alone markedly induced ALPL mRNA expression; PDGF alone had no effect on ALPL expression. Intriguingly, PDGF markedly enhanced the TGF-β-induced upregulation of ALP mRNA expression. In addition, TGF-β and PDGF greatly induced IBSP expression, although neither regulator alone was sufficient to influence IBSP expression (Fig. 2E). These regulators, either alone or synergistically, had no effect on the transcript expression of other osteogenic differentiation marker genes, such as RUNX2, COL1A1, SPP1 and BGLAP (Fig. 2A, C, D and F, respectively).
PDGF enhances the TGF-β-induced osteogenic differentiation of hMSCs on a proprietary hydroxyapatite substitute for bone mineral (Osteologic discs)
As shown in Figs. 1 and 2B, PDGF enhanced the TGF-β-induced osteogenic differentiation of hMSCs, whereas PDGF alone had no effect on differentiation. These results suggest TGF-β is superior to PDGF in the hierarchy that mediates the osteogenic differentiation of hMSCs. However, as shown in Fig. 2E, it was unclear which growth factor is the main regulator of IBSP mRNA expression. In order to clearly rank these growth factors in the context of promoting OB differentiation, we examined the mechanisms through which TGF-β and/or PDGF affect the differentiation of hMSCs on a proprietary hydroxyapatite substitute for bone mineral (Osteologic discs), instead of the plastic culture plates utilized in Figs. 1 and 2. The surface of the Osteologic cell culture disc is coated with calcium phosphate as described in Materials and methods. As shown in Fig. 3A, ALP staining of the UE7T-13 cells cultured on Osteologic discs revealed that PDGF clearly enhanced the TGF-β-induced upregulation of ALP expression, whereas PDGF alone did not. In addition, as shown in Fig. 3B and C, qRT-PCR revealed that PDGF clearly enhanced the TGF-β-induced upregulation of ALPL and IBSP transcript expression, whereas PDGF alone did not. Thus, the Osteologic culture system clearly demonstrated that TGF-β is superior to PDGF in the regulation of the osteogenic differentiation of hMSCs.
TGF-β upregulates the PDGF-induced Akt activity, whereas PDGF downregulates the TGF-β-induced ERK activity
In order to identify the signaling pathways activated by TGF-β and/or PDGF during the osteogenic differentiation of UE7T-13 cells, we evaluated the phosphorylation status of the PI3K/Akt- and ERK-mediated pathways. Gharibi et al previously reported that the PDGF BB-induced crosstalk between these pathways affects the proliferation and adipogenic commitment of hMSCs: PDGF-BB-induced PI3K/Akt signaling enhanced the proliferative activity of the hMSCs, and PDGF-BB-induced ERK-mediated signaling suppressed the adipogenic differentiation of hMSCs (48). In general, cell proliferation is poorly compatible with differentiation and proliferation/differentiation switches have been demonstrated in different cell types (49–51). In addition, a reciprocal correlation exists between the adipogenetic and osteogenetic differentiation of undifferentiated mesenchymal cells (52–54). Thus, the crosstalk between the PI3K/Akt- and ERK-mediated pathways appears to affect the osteogenic commitment of hMSCs. In our study, ERK phosphorylation was upregulated by stimulation with TGF-β alone, but Akt phosphorylation was unaffected (Fig. 4). By contrast, Akt phosphorylation was upregulated by stimulation with PDGF alone, but ERK phosphorylation was not. The phosphorylation of both ERK and Akt was detected after co-stimulation of PDGF and TGF-β. Notably, the combined stimulation of TGF-β and PDGF strongly induced Akt phosphorylation (Fig. 4B; bar graph on upper panel, lanes 10–13), whereas PDGF alone only moderate induced Akt phosphorylation (Fig. 4B; bar graph on upper panel, lanes 2–5). By contrast, TGF-β alone markedly induced ERK phosphorylation (Fig 4B; bar graph on lower panel, lanes 8 and 9), whereas the combination of TGF-β and PDGF moderately induced ERK phosphorylation (Fig 4B; bar graph on lower panel, lanes 12 and 13). No phosphorylation of Smad2/3 was detected, although it is one of the major pathways of TGF-β stimulation in these cells (data not shown).
PDGF-induced PI3K-mediated signaling enhances the TGF-β-induced, MEK-dependent osteogenic differentiation of hMSCs
As shown in Fig. 5, TGF-β alone markedly induced ECM mineralization in a MEK-dependent manner (Fig. 5; lanes 2 and 3); moreover, PDGF clearly enhanced the TGF-β-induced ECM mineralization (Fig. 5; lane 6), whereas PDGF alone had no effect (Fig. 5; lane 4). The synergistically induced ECM mineralization was completely suppressed by U0126 (a MEK inhibitor) (Fig. 5; lane 7) and only partially suppressed by LY294002 (a PI3K inhibitor) (Fig. 5; lane 8). The level of ECM mineralization was lower in the culture supplemented with TGF-β, PDGF and LY294002 (Fig. 5; lane 8) than in the culture supplemented with TGF-β alone (Fig. 5; lane 2).
Discussion
TGF-β is crucial for connective tissue regeneration and bone remodeling, as demonstrated by several in vivo and in vitro studies. It affects osteogenic differentiation and bone formation (55–59) and increases the mRNA levels of osteogenic differentiation markers and ALP activity in murine bone marrow MSCs (57). In this study, we investigated whether TGF-β promotes the osteogenic differentiation of the human bone marrow-derived MSC line, UE7T-13. Our results demonstrated that TGF-β induced the osteogenic differentiation of UE7T-13 in a dose-dependent manner (1.0–5.0 ng/ml) (Fig. 1A). Thus, we focused on the synergistic effects of multiple growth factors on the osteogenic differentiation of MSCs.
PDGF is mainly produced by platelets and has tissue repair functions, such as fracture repair (26). In addition, PDGF is a chemoattractant or mitogen of osteogenic mesenchymal cells (41), and does not seem to directly affect the osteogenic differentiation of MSCs. As shown in Fig. 1B, PDGF alone did not induce ECM mineralization in the UE7T-13 cells; however, PDGF markedly enhanced the TGF-β-induced ECM mineralization.
We also investigated the synergistic effects of TGF-β and PDGF on the mRNA expression of osteogenic differentiation marker genes. qRT-PCR revealed that the transcript expression of ALPL, a mineralization-associated enzyme, was increased by stimulation with TGF-β alone (Fig. 2B). PDGF markedly enhanced the TGF-β induction of ALPL, whereas PDGF alone had no effect. The TGF-β-induced ALPL expression was similarly and greatly increased by PDGF stimulation, whereas PDGF alone had no effect (data not shown). It is now well established that osteogenic differentiation is marked by sequential stages of cellular proliferation and ECM maturation (60). ALPL expression is a transient early marker of osteogenic differentiation in MSCs, peaking at the end of the proliferative stage before ECM maturation (61). Therefore, our findings suggest that the PDGF support of TGF-β-induced osteogenic differentiation may be important during the early stages of the osteogenesis of MSCs.
IBSP expression is restricted to mineralized connective tissues (62). IBSP is a phosphorylated, sulfated glycoprotein that represents one of the major non-collagenous ECM proteins associated with mineralized tissues (63–65). A high expression of IBSP coincides with de novo bone formation (62). IBSP is primarily expressed by mature OBs and osteoclasts, as well as by hypertrophic chondrocytes (66). We previously reported that OB-like SaOS-2 cells have an increased expression of IBSP on titanium surfaces coated with hydroxyapatite (67). Thus, the expression of IBSP is a useful indicator of osteogenic differentiation. IBSP expression occurs at the middle-to-late-stages of osteogenic differentiation of undifferentiated mesenchymal cells (68). In our study, IBSP mRNA expression was detected only in cultures containing both TGF-β and PDGF, but was not detected in the cultures containing TGF-β or PDGF alone (Fig. 2E). The bone surface is comprised of hydroxyapatite, a calcium phosphate mineral, on which MSCs differentiate into OBs; this of course differs significantly from a polystyrene culture dish surface. Therefore, we examined the osteogenic response of hMSCs to TGF-β and/or PDGF in cultures grown on Osteologic discs, a proprietary hydroxyapatite substitute. As shown in Fig. 3C, TGF-β alone markedly induced IBSP mRNA expression in the UE7T-13 cells cultured on Osteologic culture discs. In addition, PDGF clearly enhanced the TGF-β-induced IBSP mRNA expression, whereas PDGF alone had no effect on IBSP in this culture system. ALP staining and qRT-PCR revealed that PDGF clearly enhanced the TGF-β-induced upregulation of ALP protein and ALPL mRNA expression; PDGF alone had no effect (Fig. 3A and B). Thus, the Osteologic culture system demonstrated that TGF-β is superior to PDGF in the osteogenic differentiation of hMSCs. The supportive effect of PDGF seems to occur during the early stage (for ALPL induction) to late stage (for IBSP induction) of osteogenic differentiation.
In order to clarify the intracellular signaling pathways that mediate the interaction between PDGF and TGF-β in the induction of the osteogenic differentiation of MSCs, we evaluated the phosphorylation status of the PI3K/Akt and ERK pathways. The MEK inhibitor, U0126, completely suppressed the TGF-β-induced ECM mineralization in the UE7T-13 cell culture (Fig. 5; lane 3); PDGF alone did not promote osteogenic activity (Fig. 5; lane 4), but enhanced the TGF-β-induced ECM mineralization (Fig. 5; lane 6). This synergistic promotion of ECM mineralization was completely suppressed by U0126 (Fig. 5; lane 7), strongly suggesting that PDGF enhances the TGF-β-induced osteogenic differentiation of hMSCs in a TGF-β-activated MEK-dependent manner. In addition, the synergistic differentiation of hMSCs by both factors was partially suppressed by the PI3K inhibitor, LY294002 (Fig. 5; lane 8). Taken together, our results indicate that PDGF-induced PI3K-mediated signaling enhances the TGF-β-induced osteogenic differentiation of hMSCs in a TGF-β-activated MEK-dependent manner. Notably, the level of ECM mineralization in the presence of TGF-β, PDGF and LY294002 (Fig. 5; lane 8) was markedly lower than that in the cultures with TGF-β alone (Fig. 5; lane 2). As described above, PDGF inhibits the TGF-β-induced MEK activity (Fig. 4B: bar graph on lower panel, lanes 12 and 13), whereas TGF-β enhances PDGF-induced Akt activity (Fig. 4B: bar graph on upper panel, lanes 10–13). These results suggest that ECM mineralization may be predominantly induced by PI3K/Akt-mediated signaling than by MEK/ERK-mediated signaling in the presence of both factors.
Thus, it can be concluded that PDGF-stimulated PI3K/Akt-mediated signaling enhances the TGF-β-induced osteogenic differentiation of hMSCs in a MEK/ERK-dependent manner. The combination of PDGF-activated PI3K/Akt and TGF-β-activated MEK mediates osteogenic differentiation which is important for optimizing the potential therapeutic use of hMSCs for bone formation. Our findings provide insight into the establishment of novel therapeutic methods for bone formation by hMSCs.
Acknowledgements
This study was supported in part, by JSPS KAKENHI (Grant nos. 25463053 to N.C., 24792149 to N.O., 25463224 to N.T., 235928640 to H.K. and 23592896 to A.I.); the Open Research Project from the Ministry of Education, Culture, Sports, Science and Technology of Japan, 2008–2012; and a Grant-in-Aid for Strategic Medical Science Research Centre from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, 2010–2014.
References
|
Karsenty G and Wagner EF: Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2:389–406. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 276:71–74. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Pittenger MF, Mackay AM, Beck SC, et al: Multilineage potential of adult human mesenchymal stem cells. Science. 284:143–147. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Docheva D, Popov C, Mutschler W and Schieker M: Human mesenchymal stem cells in contact with their environment: surface characteristics and the integrin system. J Cell Mol Med. 11:21–38. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Baksh D, Song L and Tuan RS: Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med. 8:301–316. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kassem M, Abdallah BM and Saeed H: Osteoblastic cells: differentiation and trans-differentiation. Arch Biochem Biophys. 473:183–187. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jones E and Yang X: Mesenchymal stem cells and bone regeneration: current status. Injury. 42:562–568. 2011. View Article : Google Scholar | |
|
Proff P and Römer P: The molecular mechanism behind bone remodelling: a review. Clin Oral Investig. 13:355–362. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lazar-Karsten P, Dorn I, Meyer G, et al: The influence of extracellular matrix proteins and mesenchymal stem cells on erythropoietic cell maturation. Vox Sang. 101:65–76. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Vidane AS, Zomer HD, Oliveira BM, et al: Reproductive stem cell differentiation: extracellular matrix, tissue microenvironment, and growth factors direct the mesenchymal stem cell lineage commitment. Reprod Sci. 20:1137–1143. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen BY, Wang X, Chen LW and Luo ZJ: Molecular targeting regulation of proliferation and differentiation of the bone marrow-derived mesenchymal stem cells or mesenchymal stromal cells. Curr Drug Targets. 13:561–571. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Soleymaninejadian E, Pramanik K and Samadian E: Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol. 67:1–8. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chau JF, Leong WF and Li B: Signaling pathways governing osteoblast proliferation, differentiation and function. Histol Histopathol. 24:1593–1606. 2009.PubMed/NCBI | |
|
Pountos I, Georgouli T, Henshaw K, et al: The effect of bone morphogenetic protein-2, bone morphogenetic protein-7, parathyroid hormone, and platelet-derived growth factor on the proliferation and osteogenic differentiation of mesenchymal stem cells derived from osteoporotic bone. J Orthop Trauma. 24:552–556. 2010. View Article : Google Scholar | |
|
Bonewald LF and Mundy GR: Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res. 250:261–276. 1990.PubMed/NCBI | |
|
Bonewald LF and Dallas SL: Role of active and latent transforming growth factor beta in bone formation. J Cell Biochem. 55:350–357. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Tang Y, Wu X, Lei W, et al: TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 15:757–765. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
He S, Liu X, Yang Y, et al: Mechanisms of transforming growth factor beta (1)/Smad signalling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts. Br J Dermatol. 162:538–546. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen G, Deng C and Li YP: TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 8:272–288. 2012. | |
|
Mbalaviele G, Abu-Amer Y, Meng A, et al: Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem. 275:14388–14393. 2000. View Article : Google Scholar | |
|
Chaudhary LR and Avioli LV: Identification and activation of mitogen-activated protein (MAP) kinase in normal human osteoblastic and bone marrow stromal cells: attenuation of MAP kinase activation by cAMP, parathyroid hormone and forskolin. Mol Cell Biochem. 178:59–68. 1998. View Article : Google Scholar | |
|
Hu Y, Chan E, Wang SX and Li B: Activation of p38 mitogen-activated protein kinase is required for osteoblast differentiation. Endocrinology. 144:2068–2074. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Einhorn TA and Trippel SB: Growth factor treatment of fractures. Instr Course Lect. 46:483–486. 1997.PubMed/NCBI | |
|
Hart CE, Bailey M, Curtis DA, et al: Purification of PDGF-AB and PDGF-BB from human platelet extracts and identification of all three PDGF dimers in human platelets. Biochemistry. 29:166–172. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Hollinger JO, Hart CE, Hirsch SN, et al: Recombinant human platelet-derived growth factor: biology and clinical applications. J Bone Joint Surg Am. 90:48–54. 2008. View Article : Google Scholar | |
|
Jayakumar A, Rajababu P, Rohini S, et al: Multi-centre, randomized clinical trial on the efficacy and safety of recombinant human platelet-derived growth factor with β-tricalcium phosphate in human intra-osseous periodontal defects. J Clin Periodontol. 38:163–172. 2011.PubMed/NCBI | |
|
Ridgway HK, Mellonig JT and Cochran DL: Human histologic and clinical evaluation of recombinant human platelet-derived growth factor and beta-tricalcium phosphate for the treatment of periodontal intraosseous defects. Int J Periodontics Restorative Dent. 28:171–179. 2008. | |
|
Nevins M, Giannobile WV, McGuire MK, et al: Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. J Periodontol. 76:2205–2215. 2005. View Article : Google Scholar | |
|
McGuire MK, Kao RT, Nevins M and Lynch SE: rhPDGF-BB promotes healing of periodontal defects: 24-month clinical and radiographic observations. Int J Periodontics Restorative Dent. 26:223–231. 2006.PubMed/NCBI | |
|
Distler JH, Hirth A, Kurowska-Stolarska M, et al: Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med. 47:149–161. 2003.PubMed/NCBI | |
|
Bouletreau PJ, Warren SM, Spector JA, et al: Hypoxia and VEGF up-regulate BMP-2 mRNA and protein expression in microvascular endothelial cells: implications for fracture healing. Plast Reconstr Surg. 109:2384–2397. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Blanquaert F, Pereira RC and Canalis E: Cortisol inhibits hepatocyte growth factor/scatter factor expression and induces c-met transcripts in osteoblasts. Am J Physiol Endocrinol Metab. 278:E509–E515. 2000.PubMed/NCBI | |
|
Franchimont N, Durant D, Rydziel S and Canalis E: Platelet-derived growth factor induces interleukin-6 transcription in osteoblasts through the activator protein-1 complex and activating transcription factor-2. J Biol Chem. 274:6783–6789. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Carano RA and Filvaroff EH: Angiogenesis and bone repair. Drug Discov Today. 8:980–989. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Andrae J, Gallini R and Betsholtz C: Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22:1276–1312. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wu E, Palmer N, Tian Z, et al: Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One. 3:e37942008. View Article : Google Scholar : PubMed/NCBI | |
|
Missbach M, Jeschke M, Feyen J, et al: A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 24:437–449. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Martelli AM, Borgatti P, Bortul R, et al: Phosphatidylinositol 3-kinase translocates to the nucleus of osteoblast-like MC3T3-E1 cells in response to insulin-like growth factor I and platelet-derived growth factor but not to the proapoptotic cytokine tumor necrosis factor alpha. J Bone Miner Res. 15:1716–1730. 2000. View Article : Google Scholar | |
|
Chaudhary LR and Hruska KA: The cell survival signal Akt is differentially activated by PDGF-BB, EGF, and FGF-2 in osteoblastic cells. J Cell Biochem. 81:304–311. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Antoniades HN: PDGF: a multifunctional growth factor. Baillieres Clin Endocrinol Metab. 5:595–613. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou B, Hao Y, Wang C, et al: Conversion of natively unstructured α-synuclein to its α-helical conformation significantly attenuates production of reactive oxygen species. J Inorg Biochem. 118:68–73. 2013. | |
|
Mori T, Kiyono T, Imabayashi H, et al: Combination of hTERT and bmi-1, E6, or E7 induces prolongation of the life span of bone marrow stromal cells from an elderly donor without affecting their neurogenic potential. Mol Cell Biol. 25:5183–5195. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Shimomura T, Yoshida Y, Sakabe T, et al: Hepatic differentiation of human bone marrow-derived UE7T-13 cells: effects of cytokines and CCN family gene expression. Hepatol Res. 37:1068–1079. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Huang H, Hu ZZ, Arighi CN and Wu CH: Integration of bioinformatics resources for functional analysis of gene expression and proteomic data. Front Biosci. 12:5071–5088. 2007.PubMed/NCBI | |
|
Dalle Carbonare L, Innamorati G and Valenti MT: Transcription factor Runx2 and its application to bone tissue engineering. Stem Cell Rev. 8:891–897. 2012.PubMed/NCBI | |
|
Neve A, Corrado A and Cantatore FP: Osteoblast physiology in normal and pathological conditions. Cell Tissue Res. 343:289–302. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gharibi B, Ghuman MS and Hughes FJ: Akt- and Erk-mediated regulation of proliferation and differentiation during PDGFRβ-induced MSC self-renewal. J Cell Mol Med. 16:2789–2801. 2012.PubMed/NCBI | |
|
Chen JF, Mandel EM, Thomson JM, et al: The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 38:228–233. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Conti L, Sipione S, Magrassi L, et al: Shc signaling in differentiating neural progenitor cells. Nat Neurosci. 4:579–586. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Dugan LL, Kim JS, Zhang Y, et al: Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem. 274:25842–25848. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Sottile V, Halleux C, Bassilana F, et al: Stem cell characteristics of human trabecular bone-derived cells. Bone. 30:699–704. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Pereira RC, Delany AM and Canalis E: Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone. 30:685–691. 2002. View Article : Google Scholar | |
|
Lecka-Czernik B, Moerman EJ, Grant DF, et al: Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology. 143:2376–2384. 2002. | |
|
Janssens K, ten Dijke P, Janssens S and Van Hul W: Transforming growth factor-beta1 to the bone. Endocr Rev. 26:743–774. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JY, Kim KH, Shin, et al: Enhanced bone formation by transforming growth factor-beta1-releasing collagen/chitosan microgranules. J Biomed Mater Res A. 76:530–539. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao L, Jiang S and Hantash BM: Transforming growth factor beta1 induces osteogenic differentiation of murine bone marrow stromal cells. Tissue Eng Part A. 16:725–733. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lee KS, Hong SH and Bae SC: Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene. 21:7156–7163. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Ripamonti U, Ferretti C, Teare J and Blann L: Transforming growth factor-beta isoforms and the induction of bone formation: implications for reconstructive craniofacial surgery. J Craniofac Surg. 20:1544–1555. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Quarles LD, Yohay DA, Lever LW, et al: Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res. 7:683–692. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Luo X, Chen J, Song WX, et al: Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest. 88:1264–1277. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Shapiro HS and Sodek J: Development expression of bone sialoprotein mRNA in rat mineralized connective tissues. J Bone Miner Res. 7:987–997. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Fisher LW, McBride OW, Termine JD and Young MF: Human bone sialoprotein: deduced protein sequence and chromosomal localization. J Biol Chem. 265:2347–2351. 1990.PubMed/NCBI | |
|
Ganss B, Kim RH and Sodek J: Bone sialoprotein. Crit Rev Oral Biol Med. 10:79–98. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Ogata Y: Bone sialoprotein and its transcriptional regulatory mechanism. J Periodontal Res. 43:127–135. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bianco P, Fisher LW, Young MF, et al: Expression of bone sialoprotein (BSP) in developing human tissues. Calcif Tissue Int. 49:421–426. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Chosa N, Taira M, Saitoh S, et al: Characterization of apatite formed on alkaline-heat-treated Ti. J Dent Res. 83:465–469. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Id Boufker H, Lagneaux L, Fayyad-Kazan H, et al: Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts. Bone. 49:1219–1231. 2011.PubMed/NCBI |
